0001179110-21-000648.txt : 20210115
0001179110-21-000648.hdr.sgml : 20210115
20210115160456
ACCESSION NUMBER: 0001179110-21-000648
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210113
FILED AS OF DATE: 20210115
DATE AS OF CHANGE: 20210115
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Utter Christine Marie
CENTRAL INDEX KEY: 0001707685
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 21532130
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
edgar.xml
FORM 4 -
X0306
4
2021-01-13
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001707685
Utter Christine Marie
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
SVP, Finance & CAO
Common Stock
2021-01-13
4
S
0
659
66.57
D
17529
D
Common Stock
2021-01-13
4
M
0
788
11.23
A
18317
D
Common Stock
2021-01-13
4
S
0
788
66.57
D
17529
D
Common Stock
2021-01-13
4
M
0
2500
18.01
A
20029
D
Common Stock
2021-01-13
4
S
0
2500
66.57
D
17529
D
Stock Option (Right To Buy)
11.23
2021-01-13
4
M
0
788
11.23
D
2027-01-02
Common Stock
788.0
0
D
Stock Option (Right to Buy)
18.01
2021-01-13
4
M
0
2500
18.01
D
2028-01-02
Common Stock
2500
10000
D
Stock Option (Right To Buy)
490.8
2021-04-27
Common Stock
74.0
74
D
Stock Option (Right To Buy)
218.4
2022-01-10
Common Stock
21.0
21
D
Stock Option (Right To Buy)
40.45
2024-09-23
Common Stock
4688.0
4688
D
Stock Option (Right To Buy)
51.0
2025-01-02
Common Stock
17800.0
17800
D
Stock Option (Right to Buy)
33.02
2029-01-21
Common Stock
23907
23907
D
Stock Option (Right To Buy)
33.02
2029-01-21
Common Stock
10100.0
10100
D
Stock Option (Right To Buy)
51.16
2030-01-28
Common Stock
23800.0
23800
D
Stock Option (Right to Buy)
66.49
2031-01-05
Common Stock
50750
50750
D
This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 14, 2020.
Currently exercisable.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
/s/ Avraham S. Adler, attorney-in-fact
2021-01-15